Evaluation of the Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride Levels greater than or equal to 500 mg/dL and less than or equal to 2000 mg/dL.

Trial Profile

Evaluation of the Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride Levels greater than or equal to 500 mg/dL and less than or equal to 2000 mg/dL.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2016

At a glance

  • Drugs Ethyl eicosapentaenoic acid (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Biomarker; Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms MARINE
  • Sponsors Amarin Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Nov 2016 Results (n=215) of subgroup analyses of MARINE and ANCHOR trials published in the American Journal of Cardiology (2016).
    • 20 May 2016 Results published in the Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top